留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

封堵卵圆孔未闭预防卒中的国外发展及中国现状

何璐 张玉顺

何璐, 张玉顺. 封堵卵圆孔未闭预防卒中的国外发展及中国现状[J]. 协和医学杂志, 2021, 12(3): 318-321. doi: 10.12290/xhyxzz.2021-0136
引用本文: 何璐, 张玉顺. 封堵卵圆孔未闭预防卒中的国外发展及中国现状[J]. 协和医学杂志, 2021, 12(3): 318-321. doi: 10.12290/xhyxzz.2021-0136
HE Lu, ZHANG Yushun. The Role of Patent Foramen Ovale Closure in the Prevention of Stroke: Development in Foreign Countries and Status in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 318-321. doi: 10.12290/xhyxzz.2021-0136
Citation: HE Lu, ZHANG Yushun. The Role of Patent Foramen Ovale Closure in the Prevention of Stroke: Development in Foreign Countries and Status in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 318-321. doi: 10.12290/xhyxzz.2021-0136

封堵卵圆孔未闭预防卒中的国外发展及中国现状

doi: 10.12290/xhyxzz.2021-0136
详细信息
    通讯作者:

    张玉顺  电话:029-85324028,E-mail: 111

  • 中图分类号: R541;R654.2

The Role of Patent Foramen Ovale Closure in the Prevention of Stroke: Development in Foreign Countries and Status in China

More Information
    Corresponding author: ZHANG Yushun  Tel: 86-29-85324028, E-mail: 111
  • 摘要: 经过近20年的争议和大量研究,封堵卵圆孔未闭(patent foramen ovale,PFO)在卒中二级预防中的作用已经明确。本文从循证医学证据入手,回顾近年来国内外经导管封堵PFO预防卒中的研究成果,旨在明确能从封堵治疗中获益的PFO人群。
    作者贡献:   何璐负责资料收集、论文撰写; 张玉顺负责论文修订、审校。
    利益冲突:   无
  • [1] Cohnheim J. Thrombose und Embolie[M]//Cohnheim J. Vorlesungenüber Allgemeine Pathologie. Berlin: Hirschwald, 1877: 134.
    [2] Nellessen U, Daniel WG, Matheis G, et al. Impending paradoxical embolism from atrial thrombus: correct diagnosis by transesophageal echocardiography and prevention by surgery[J]. J Am Coll Cardiol, 1985, 5: 1002-1004. doi:  10.1016/S0735-1097(85)80449-6
    [3] Brogno DJ, Lancaster G, Rosenbaum M. Embolus Interuptus[J]. N Engl J Med, 1994, 330: 1761-1762. doi:  10.1056/NEJM199406163302419
    [4] Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism[J]. Circulation, 1992, 86: 1902-1908. doi:  10.1161/01.CIR.86.6.1902
    [5] Wahl A, Jüni P, Mono ML, et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism[J]. Circulation, 2012, 125: 803-812. doi:  10.1161/CIRCULATIONAHA.111.030494
    [6] Agarwal S, Bajaj NS, Kumbhani DJ, et al. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism[J]. JACC Cardiovasc Interv, 2012, 5: 777-789. doi:  10.1016/j.jcin.2012.02.021
    [7] Gafoor S, Franke J, Boehm P, et al. Leaving no hole unclosed: left atrial appendage occlusion in patients having closure of patent foramen ovale or atrial septal defect[J]. J Interv Cardiol, 2014, 27: 414-422. doi:  10.1111/joic.12138
    [8] Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale[J]. N Engl J Med, 2012, 366: 991-999. doi:  10.1056/NEJMoa1009639
    [9] Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke[J]. N Engl J Med, 2013, 368: 1092-1100. doi:  10.1056/NEJMoa1301440
    [10] Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism[J]. N Engl J Med, 2013, 368: 1083-1091. doi:  10.1056/NEJMoa1211716
    [11] Taaffe M, Fischer E, Baranowski A, et al. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus Cardioseal-StarFlex versus Helexoccluder)[J]. Am J Cardiol, 2008, 101: 1353-1358. doi:  10.1016/j.amjcard.2007.12.040
    [12] Hornung M, Bertog SC, Franke J, et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale[J]. Eur Heart J, 2013, 34: 3362-3369. doi:  10.1093/eurheartj/eht283
    [13] Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J]. N Engl J Med, 2017, 377: 1011-1021. doi:  10.1056/NEJMoa1705915
    [14] Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J]. N Engl J Med, 2017, 377: 1033-1042. doi:  10.1056/NEJMoa1707404
    [15] Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J]. N Engl J Med, 2017, 377: 1022-1032. doi:  10.1056/NEJMoa1610057
    [16] Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSE-PFO trial[J]. J Am Coll Cardiol, 2018, 71: 2335-2342. doi:  10.1016/j.jacc.2018.02.046
    [17] Wein T, Lindsay MP, Côte R, et al. Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017[J]. Int J Stroke, 2018, 13: 420-443. doi:  10.1177/1747493017743062
    [18] Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline[J]. BMJ, 2018, 362: k2515. http://europepmc.org/articles/PMC6058599/
    [19] Mas JL, Derex L, Guérin P, et al. Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology[J]. Arch Cardiovasc Dis, 2019, 112: 532-542. doi:  10.1016/j.acvd.2019.06.002
    [20] Ntaios G, Tzikas A, Vavouranakis E, et al. Expert consen-sus statement for the management of patients with embolic stroke of undetermined source and patent foramen ovale: A clinical guide by the working group for stroke of the Hellenic Society of Cardiology and the Hellenic Stroke Organization[J]. Hell J Cardiol, 2020, 61: 435-441. doi:  10.1016/j.hjc.2020.02.001
    [21] Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology[J]. Neurology, 2020, 94: 876-885. doi:  10.1212/WNL.0000000000009443
    [22] 张玉顺, 代政学, 贾国良. 卵圆孔未闭与反常栓塞的研究进展[J]. 心脏杂志, 2001, 13: 319-321. doi:  10.3969/j.issn.1009-7236.2001.04.027
    [23] Hao N, Liu KD, Guo ZN, et al. Comparison of two contrast agents for right-to-left shunt diagnosis with contrast-enhanced transcranial doppler[J]. Ultrasound Med Biol, 2014, 40: 2317-2320. doi:  10.1016/j.ultrasmedbio.2014.03.011
    [24] Guo YZ, Gao YS, Guo ZN, et al. Comparison of different methods of Valsalva maneuver for right-to-left shunt detection by contrast-enhanced transcranial doppler[J]. Ultrasound Med Biol, 2016, 42: 1124-1129. doi:  10.1016/j.ultrasmedbio.2015.12.020
    [25] 中国医师协会心血管内科医师分会. 卵圆孔未闭处理策略中国专家建议[J]. 心脏杂志, 2015, 27: 373-379. https://www.cnki.com.cn/Article/CJFDTOTAL-XGNZ201504002.htm
    [26] 中华医学会心血管内科分会, 中国医师协会心血管内科分会. 卵圆孔未闭预防性封堵术中国专家共识[J]. 心脏杂志, 2015, 32: 209-214. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201703002.htm
    [27] 张玉顺, 蒋世良, 朱鲜阳, 等. 卵圆孔未闭相关卒中预防中国专家指南[J]. 心脏杂志, 2021, 33: 1-10. doi:  10.12125/j.chj.202101022
    [28] 王文婷, 黄海韵, 柳强维, 等. 经胸超声心动图结合右心声学造影在判断卵圆孔未闭右向左分流中的临床价值[J]. 第三军医大学学报, 2017, 39: 1648-1653. https://www.cnki.com.cn/Article/CJFDTOTAL-DSDX201716011.htm
  • 加载中
计量
  • 文章访问数:  86
  • HTML全文浏览量:  28
  • PDF下载量:  73
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-01
  • 录用日期:  2021-03-23
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回